Gefitinib monotherapy in advanced non-small-cell lung cancer: a retrospective analysis.
S Shrestha, P Joshi - Journal of the Nepal Medical …, 2012 - search.ebscohost.com
Introduction: There is no published data in Nepal regarding the use of gefitinib in patients
with non-small cell lung cancer (NSCLC). Therefore, a retrospective analysis was conducted …
with non-small cell lung cancer (NSCLC). Therefore, a retrospective analysis was conducted …
[HTML][HTML] The role of gefitinib in patients with non-small-cell lung cancer in India
Background: Gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor,
represents a new treatment option for patients with advanced non-small-cell lung cancer …
represents a new treatment option for patients with advanced non-small-cell lung cancer …
Gefitinib in advanced non‐small cell lung cancer
R Sharma, M Boyer, S Clarke… - Internal medicine …, 2005 - Wiley Online Library
Background: Gefitinib is an oral, selective epidermal growth factor receptor (EGFR) inhibitor
that has activity in non‐small cell lung cancer (NSCLC). Aim: To evaluate the tolerability …
that has activity in non‐small cell lung cancer (NSCLC). Aim: To evaluate the tolerability …
Gefitinib in patients with non-small cell lung cancer (NSCLC): the Royal Marsden experience
M Parton, N Maisey, S Banerjee… - Journal of Clinical …, 2004 - ascopubs.org
7099 Background: Gefitinib (Iressa), an inhibitor of the intracellular tyrosine kinase domain,
has demonstrated useful activity in advanced pre-treated NSCLC (IDEAL I/II). The clinical …
has demonstrated useful activity in advanced pre-treated NSCLC (IDEAL I/II). The clinical …
Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University experience
A Kommareddy, MA Coplin, F Gao, D Behnken… - Lung Cancer, 2004 - Elsevier
Gefitinib has modest activity with an overall response rate of 11–18% in patients with
metastatic non-small cell lung cancer (NSCLC) who have had progressive disease following …
metastatic non-small cell lung cancer (NSCLC) who have had progressive disease following …
Gefitinib as First‐line Therapy for Advanced or Metastatic Non‐small Cell Lung Cancer Patients in Southern Taiwan
CT Yang, JY Hung, CL Lai, HC Hung… - … Journal of Medical …, 2010 - Wiley Online Library
Gefitinib, a selective epidermal growth factor receptor tyrosine kinase inhibitor, is effective in
treating patients with non‐small cell lung cancer (NSCLC) after unsuccessful chemotherapy …
treating patients with non‐small cell lung cancer (NSCLC) after unsuccessful chemotherapy …
[HTML][HTML] Clinical experience with gefitinib in Indian patients
P Parikh, AYC Chang, S Nag, R Digumarti… - Journal of Thoracic …, 2008 - Elsevier
Introduction Treatment options are limited in patients with advanced or refractory non-small
cell lung cancer and lead to suboptimal outcome and/or benefit. The epidermal growth factor …
cell lung cancer and lead to suboptimal outcome and/or benefit. The epidermal growth factor …
Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania
ML Veronese, K Algazy, L Bearn, B Eaby… - Cancer …, 2005 - Taylor & Francis
Gefitinib (Iressa; AstraZeneca Pharmaceuticals, Wilmington, DE) is an oral epidermal growth
factor receptor tyrosine kinase inhibitor (EGFR-TKI) with favorable toxicity and antitumor …
factor receptor tyrosine kinase inhibitor (EGFR-TKI) with favorable toxicity and antitumor …
Gefitinib Therapy for Advanced Non–Small-Cell Lung Cancer
CY Liu, S Seen - Annals of Pharmacotherapy, 2003 - journals.sagepub.com
OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, and toxicity of
gefitinib in non–small-cell lung cancer (NSCLC). DATA SOURCES: Primary literature search …
gefitinib in non–small-cell lung cancer (NSCLC). DATA SOURCES: Primary literature search …
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer
M Fukuoka, S Yano, G Giaccone, T Tamura… - Journal of clinical …, 2003 - ascopubs.org
Purpose: To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839];
AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase …
AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase …